We focus on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide flexible, long term capital to help accelerate their ideas into important new treatments for patients.
We are science led investors, focusing on innovative technologies in areas of high unmet need. Unconstrained by institution, geography or stage of company development we have the ability to source the best life science innovation without restriction.
Click here to see our operations in full.
UK & US.
Joe Anderson, PhD
Chief Executive Officer, London, UK
Joe has over 25 years’ experience in the life sciences industry with a successful track record of generating investment returns. He was a partner at Abingworth LLP for 12 years, where he led venture-capital style investments in public companies. He has founded and managed public equities funds and been a director of Algeta (acquired by Bayer AG for $2.9 billion), Amarin plc, Cytos (merged with Kuros) and Epigenomics AG, and is currently a director of Autolus Therapeutics.
Joe began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became head of the strategy team. He then moved to the City of London as a pharmaceuticals analyst at Dresdner Kleinwort Benson before being appointed as Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. Joe has a PhD in Biochemistry and extensive board level experience of building successful life science companies.
Chief Financial Officer, London, UK
James has substantial experience at board and senior management level gained over 20 years of involvement in financial services and UK public companies. James’ former role was Group CFO of Charles Stanley plc, a leading investment manager with over £20 billion of funds under management and administration.
Previously, James was Group CFO for Coutts, the Private Bank and Wealth Manager, where he had global responsibility for Finance and held a key role in setting strategy. Before this James spent three years in UBS Wealth Management’s head office in Zurich, having previously acted as CFO for UBS Wealth UK.
Chief Operating Officer and General Counsel, London, UK
Robert has over 10 years' experience working with high growth technology companies. In addition to his role as Chief Operating Officer, Robert acts as the Company's General Counsel and Company Secretary.
He began his career as a lawyer at international law firm Bird & Bird LLP in London. He has advised on over 60 venture capital financings in Europe and North America as well as multiple trade exits and IPOs, working with both company boards and investors to execute complex cross-border transactions.
Robert Joined Arix in 2017 from Touchstone Innovations plc where he worked with a number of venture-backed biotechnology companies, both private and public.
Robert has a BA from the University of Oxford and an LLB from Oxford Brookes University.
Rob is an experienced general counsel with particular expertise in venture capital having advised on over 50 VC rounds in Europe and North America as well as multiple trade exits and IPOs. Rob assists with all of Arix’s corporate and transactional matters in addition to acting as the Company Secretary. He sits on the board of Arix Capital Management and is the regulated entity’s CF10 and CF11.
Rob joined Arix from Touchstone Innovations plc and prior to this was an associate at the international law firm Bird & Bird LLP. Rob has a BA from the University of Oxford and an LLB from Oxford Brookes University.
Jonathan Tobin, PhD
Investment Director, London, UK
Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma, Atox Bio, Mitoconix Bio and Arix's New SeedCo. Prior to joining Arix Bioscience, Jonathan spent five years at Touchstone Innovations (formerly Imperial Innovations), where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies. Jonathan also worked at MRC Technology, sourcing and evaluating new small molecule and antibody drug discovery projects.
He has a first-class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan also has an MBA with distinction from Imperial College, and is a Trustee of the Autism Research Trust.
Investment Director, New York, US
Mark has over 10 years of experience in the life sciences industry. He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech. Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.
Investment Director, London, UK
Ed is an Investment Director at Arix and sits on the board of Depixus. Before joining Arix Bioscience at its inception, Ed spent 18 years as an equity analyst and Portfolio Manager in Europe and Australia. From 2004 to 2014, he was Head of Research at Alliance Bernstein and then a senior portfolio manager at AMP Capital, a leading Australian investment house with over A$130bn in funds under management, both in Sydney, Australia. At AMP Capital, he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the Healthcare sector.
Prior to his move to Australia, Ed analysed European equities at UBS Asset Management and JP Morgan Investment Management. He gained an MA in Chemistry and MSc in Management at the University of Oxford and is a Chartered Financial Analyst.
Daniel O’Connell, MD, PhD
Investment Director, New York, US
Daniel has over 10 years of experience in healthcare. Daniel joined Arix Bioscience from OrbiMed Advisors, where he played key roles across investments in both biotherapeutics and medical devices. Investments he has supported include CardiAQ (acquired by Edwards), Civitas Therapeutics (acquired by Acorda), Relypsa (acquired by Galenica), Cynapsus (acquired by Sunovion), as well as other public and private companies. Prior to OrbiMed, Daniel was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals where he was responsible for pre-IND discovery and development for programs in lipid modulation. He received his MD and PhD in Biochemistry from Tufts University School of Medicine, and has undergraduate degrees in Mathematics and Chemistry from MIT.
Christian Schetter, PhD
Entrepreneur in Residence, Munich, Germany
Christian has over 20 years’ experience in the life science industry. Prior to joining Arix Bioscience he was for four years CEO of Rigontec GmbH, a German Biotech start-up company in the immune oncology space. Christian lead Rigontec to a successful acquisition mid 2017 by MSD valuing EUR 115 MM in upfront payment and additional EUR 349 MM in potential milestones. Between 2008 and 2014 Christian was President and CEO of Neovii Biotech, previously Fresenius Biotech. During his tenure one antibody product was brought to market and the indication for another product expanded. Christian was instrumental in selling Fresenius Biotech to the Neopharm Group, Israel, to form Neovii Biotech and positioning it as a successful standalone business. Before joining Fresenius, Christian was Senior Vice President, European Operations of Coley Pharmaceutical Group, Inc, a pioneer in the development of immunostimulatory oligonucleotides, and served as Managing Director of Coley GmbH. He was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following a number of significant pharma deals, to a trade sale to Pfizer in 2007.
Before entering the life science industry Christian was successfully performing academic research at the Max Planck Institute in Martinsried, Germany. He received his undergraduate degree and PhD from the University of Cologne and did postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California.
John Cassidy, PhD
Associate, London, UK
John Cassidy joined Arix Bioscience in February 2018. John previously worked at L.E.K. Consulting LLP, as a Consultant in the Life Sciences practice, responsible for strategy and transaction support for pharma, biotech and private equity clients. John has a first-class degree in Biochemistry from Imperial College London and a PhD in Neuroscience from University College London sponsored by the Medical Research Council and Pfizer. John has published research in journals including Proceedings of the National Academy of Sciences (PNAS), Nature Communications, eLife and Journal of Neuroscience. John is also a board observer for Imara and Arix’s New SeedCo.